Abstract:Objective To investigate the effects of rosiglitazone on the proliferation,connective tissue growth factor and Smad expression in cultured cardiac fibroblasts induced by advanced glycosylation end-products (AGEs).Methods After being treated with various amounts of rosiglitazone,the cultured neonatal rat cardiac fibroblasts were incubated with AGEs.The status of cardiac fibroblasts proliferation and cell cycle were detected by 3-(4,5-dimethyhhiazol-2-yl) -2,5-diphenyl tetrazolium bromide (MTI) assay and flow cytometry.Furthermore,ELISA technique was applied to identify the level of TGF-β1.The protein expressions of CTGF and Smad in cardiac fibroblasts of neonatal SD rats were detected with Western blotting.Results The exposure of cardiac fibroblasts to AGEs at doses of 0-200 mg/L induced a dose-dependent increase in cell proliferation.At the concentration of rosiglitazooe (0.1,1,and 10 μmol/L),the cell proliferation was reduced compared with 200 mg/L AGEs group by O.823±0.072,0.785±0.060,0.601±0.081 vs 0.981±0.049,respectively (P < 0.05).The increased levels of TGF-β1 in supematants of cultured cardiac fibroblasts stimulated by AGEs were inhibited by rosiglitazone at the concentrations of 0.1,1,10μmol/L by 257.77±9.09,230.29±6.56,200.84±10.26 vs 300.68±8.56,respectively (vs 200 mg/L AGEs,P<0.01).Western blot indicated that pretreatment with rosiglitazone (0.1,1,and 10 μmol/L) inhibited CTGF protein production in a dose-dependent by 0.769±0.108,0.590±0.095,0.534±0.115 vs 1.021±0.113,respectively (vs 200 mg/L AGEs,P<0.01).It was also demonstrated that pretreatment with rosiglitazone (1 and 10 μmol/L) inhibited Smad2 protein production by 0.424±0.059,0.396±O.080 vs 0.572±0.073,respectively (vs 200 mg/L AGEs,P < 0.05 or P < 0.01).Meanwhile pretreatment with rosiglitazone (1 and 10 μmol/L) inhibited Smad4 protein production by 0.580±0.063,0.556±0.051 vs 0.672±0.059,respectively (vs 200 mg/L AGEs,P < 0.05 or P < 0.01).Conclusions The findings suggest that AGEs promote the proliferation of cardiac fibroblasts and stimulate the protein production of Smad and CTGF of cardiac fibroblasts.Rosiglitazone inhibits the above reaction.These results indicate that CTGF/Smad pathway may play an important role in the protective effect of rosiglitazone on myocardial fibrosis.

Effect of rosiglitazone on oxidative stress and collagen metabolism in rat cardiac fibroblasts induced by advanced glycation end products

Effect of rosiglitazone on cardiac fibroblast proliferation, nitric oxide production and connective tissue growth factor expression induced by advanced glycation end-products.

Rosiglitazone ameliorates the dysfunction of endothelial progenitor cells induced by advanced glycation end products

Rosiglitazone Via Upregulation of Akt/Enos Pathways Attenuates Dysfunction of Endothelial Progenitor Cells, Induced by Advanced Glycation End Products

Effect of Rosiglitazone on the Proliferation and NO Secretion of Cultured Cardiac Fibroblasts Induced by AGEs

Inhibition of Rosiglitazone on the Proliferation, Connective Tissue Growth Factor and Smad Expression in Cultured Cardiac Fibroblasts Induced by Advanced Glycosylation End-Products

Effects of Rosiglitazone on Serum Levels of Lipids and Inflammatory Factors in Atherosclerotic Rats

Rosiglitazone inhibits the expression of β1-integrin in cultured HRMCs incubated with AGEs

Effect of rosiglitazone on the myocardial interstitial fibrosis and cytokines expression of diabetic rats

Rosiglitazone Prevents Advanced Glycation End Products-Induced Renal Toxicity Likely Through Suppression of Plasminogen Activator Inhibitor-1.

Effects of rosiglitazone on myocardial fibrosis and expression of nuclear factorkappa B activation and connective tissue growth factor in diabetic rats

Rosiglitazone maleate inhibits the hyperexpression of RANTES induced by advanced glycosylation end products in human renal mesangial cells (HRMC)

Mechanism of Rosiglitazone on Advanced Glycation End Products Induced Calcification in Rat Vascular Smooth Muscle Cells

Reduction of serum advanced glycosylation end products-peptides and monocyte chemoattractant protein-1 by rosiglitazone in type 2 diabetic rats

Rosiglitazone improved advanced glycation end products-induced calcification in vitro by suppressing receptor for AGEs expression

Effect of rosiglitazone on the expression of fractalkine in renal cortex of type 2 diabetic rats

On the expression of fractalkine by rosiglitazone in human renal mesangial cells induced by advanced glycation end products

Effects of rosiglitazone on rat aortic adventitial fibroblasts migration induced by angiotensinⅡ

Protective effect of rosiglitazone on cardiomyocytes injured by ET-1 and its mechanism

Rosiglitazone Inhibits Angiotensin II-induced CTGF Expression in Vascular Smooth Muscle Cells––role of PPAR-γ in Vascular Fibrosis